Alexandrov L.B.

Nik-Zainal S.

Wedge D.C.

Aparicio S.A.

Behjati S.

Biankin A.V.

Bignell G.R.

Bolli N.

Borg A.

Børresen-Dale A.L.

et al.

Australian Pancreatic Cancer Genome Initiative

ICGC Breast Cancer Consortium

ICGC MMML-Seq Consortium

ICGC PedBrain Signatures of mutational processes in human cancer. Nature. 500 : 415-421 View in Article Scopus (3897)

PubMed

Crossref

Google Scholar

Anagnostou V.

Smith K.N.

Forde P.M.

Niknafs N.

Bhattacharya R.

White J.

Zhang T.

Adleff V.

Phallen J.

Wali N.

et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 7 : 264-276 View in Article Scopus (270)

PubMed

Crossref

Google Scholar

Antonia S.J.

Villegas A.

Daniel D.

Vicente D.

Murakami S.

Hui R.

Yokoi T.

Chiappori A.

Lee K.H.

de Wit M.

et al.

PACIFIC Investigators Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 377 : 1919-1929 View in Article Scopus (1029)

PubMed

Crossref

Google Scholar

Argiles G.

Saro J.

Segal N.H.

Melero I.

Ros W.

Marabelle A.

Rodriguez M.E.

Albanell J.

Calvo E.

Moreno V.

et al. Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann. Oncol. 28 ( ) View in Article PubMed

Abstract

Full Text

Full Text PDF

Google Scholar

Atkins M.B.

Plimack E.R.

Puzanov I.

Fishman M.N.

McDermott D.F.

Cho D.C.

Vaishampayan U.N.

George S.

Olencki T.

Tarazi J.C.

et al. Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). Journal of Clinial Onocology. 36 ( ) View in Article Google Scholar

Ayers M.

Lunceford J.

Nebozhyn M.

Murphy E.

Loboda A.

Kaufman D.R.

Albright A.

Cheng J.D.

Kang S.P.

Shankaran V.

et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127 : 2930-2940 View in Article Scopus (542)

PubMed

Crossref

Google Scholar

Ayers M.

Nebozhyn M.

Cristescu R.

McClanahan T.K.

Perini R.

Rubin E.

Cheng J.D.

Kaufman D.R.

Loboda A. Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clin. Cancer Res. 25 : 1564-1573 View in Article Scopus (6)

PubMed

Crossref

Google Scholar

Bacac M.

Fauti T.

Sam J.

Colombetti S.

Weinzierl T.

Ouaret D.

Bodmer W.

Lehmann S.

Hofer T.

Hosse R.J.

et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clin. Cancer Res. 22 : 3286-3297 View in Article Scopus (89)

PubMed

Crossref

Google Scholar

Bargou R.

Leo E.

Zugmaier G.

Klinger M.

Goebeler M.

Knop S.

Noppeney R.

Viardot A.

Hess G.

Schuler M.

et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 321 : 974-977 View in Article Scopus (681)

PubMed

Crossref

Google Scholar

Barker A.D.

Sigman C.C.

Kelloff G.J.

Hylton N.M.

Berry D.A.

Esserman L.J. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86 : 97-100 View in Article Scopus (407)

PubMed

Crossref

Google Scholar

Botticelli A.

Salati M.

Di Pietro F.R.

Strigari L.

Cerbelli B.

Zizzari I.G.

Giusti R.

Mazzotta M.

Mazzuca F.

Roberto M.

et al. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. J. Transl. Med. 17 : 99 View in Article Scopus (2)

PubMed

Crossref

Google Scholar

Bray F.

Ferlay J.

Soerjomataram I.

Siegel R.L.

Torre L.A.

Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 : 394-424 View in Article Scopus (12109)

PubMed

Crossref

Google Scholar

Carbone D.P.

Reck M.

Paz-Ares L.

Creelan B.

Horn L.

Steins M.

Felip E.

van den Heuvel M.M.

Ciuleanu T.E.

Badin F.

et al.

CheckMate 026 Investigators First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N. Engl. J. Med. 376 : 2415-2426 View in Article Scopus (835)

PubMed

Crossref

Google Scholar

Carvajal-Hausdorf D.

Altan M.

Velcheti V.

Gettinger S.N.

Herbst R.S.

Rimm D.L.

Schalper K.A. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J. Immunother. Cancer. 7 : 65 View in Article Scopus (16)

PubMed

Crossref

Google Scholar

Chau I.

Haag G.M.

Rahma O.E.

Macarulla T.M.

McCune S.L.

Yardley D.A.

Solomon B.J.

Johnson M.

Vidal G.A.

Schmid P.

et al. 1239TiP MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Ann. Oncol. 29 ( ) View in Article Abstract

Full Text

Full Text PDF

Google Scholar

Chawla A.

Peeples M.

Li N.

Anhorn R.

Ryan J.

Signorovitch J. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. J. Med. Econ. 21 : 543-552 View in Article Scopus (1)

PubMed

Crossref

Google Scholar

Chen D.S. Meet the Expert: The Cancer-Immune Set Point and the Future of Cancer Immunotherapy. American Association for Cancer Research , View in Article Google Scholar

Cherkasova E.

Weisman Q.

Childs R.W. Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors. Front. Oncol. 3 : 243 View in Article Scopus (16)

PubMed

Crossref

Google Scholar

Claret L.

Jin J.Y.

Ferte C.

Winter H.

Girish S.

Stroh M.

He P.

Ballinger M.

Sandler A.

Joshi A.

et al. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clin. Cancer Res. 24 : 3292-3298 View in Article Scopus (5)

PubMed

Crossref

Google Scholar

Czuczman M.S.

Weaver R.

Alkuzweny B.

Berlfein J.

Grillo-López A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22 : 4711-4716 View in Article Scopus (322)

PubMed

Crossref

Google Scholar

Dirix L.Y.

Takacs I.

Jerusalem G.

Nikolinakos P.

Arkenau H.T.

Forero-Torres A.

Boccia R.

Lippman M.E.

Somer R.

Smakal M.

et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167 : 671-686 View in Article Scopus (142)

PubMed

Crossref

Google Scholar

Efremova M.

Rieder D.

Klepsch V.

Charoentong P.

Finotello F.

Hackl H.

Hermann-Kleiter N.

Lower M.

Baier G.

Krogsdam A.

Trajanoski Z. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat. Commun. 9 : 32 View in Article Scopus (35)

PubMed

Crossref

Google Scholar

Eroglu Z.

Zaretsky J.M.

Hu-Lieskovan S.

Kim D.W.

Algazi A.

Johnson D.B.

Liniker E.

Ben Kong

Munhoz R.

Rapisuwon S.

et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 553 : 347-350 View in Article Scopus (84)

PubMed

Crossref

Google Scholar

Faroudi M.

Utzny C.

Salio M.

Cerundolo V.

Guiraud M.

Müller S.

Valitutti S. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA. 100 : 14145-14150 View in Article Scopus (145)

PubMed

Crossref

Google Scholar

Freeman G.J.

Long A.J.

Iwai Y.

Bourque K.

Chernova T.

Nishimura H.

Fitz L.J.

Malenkovich N.

Okazaki T.

Byrne M.C.

et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 : 1027-1034 View in Article Scopus (2771)

PubMed

Crossref

Google Scholar

Freeman-Keller M.

Kim Y.

Cronin H.

Richards A.

Gibney G.

Weber J.S. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin. Cancer Res. 22 : 886-894 View in Article Scopus (305)

PubMed

Crossref

Google Scholar

Gandara D.R.

Paul S.M.

Kowanetz M.

Schleifman E.

Zou W.

Li Y.

Rittmeyer A.

Fehrenbacher L.

Otto G.

Malboeuf C.

et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24 : 1441-1448 View in Article Scopus (220)

PubMed

Crossref

Google Scholar

Gandhi L.

Rodríguez-Abreu D.

Gadgeel S.

Esteban E.

Felip E.

De Angelis F.

Domine M.

Clingan P.

Hochmair M.J.

Powell S.F.

et al.

KEYNOTE-189 Investigators Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N. Engl. J. Med. 378 : 2078-2092 View in Article Scopus (1193)

PubMed

Crossref

Google Scholar

Gauci M.L.

Lanoy E.

Champiat S.

Caramella C.

Ammari S.

Aspeslagh S.

Varga A.

Baldini C.

Bahleda R.

Gazzah A.

et al. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin. Cancer Res. 25 : 946-956 View in Article Scopus (21)

PubMed

Crossref

Google Scholar

Gentilini A.

Pastore M.

Marra F.

Raggi C. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Int. J. Mol. Sci. 19 : 2885 View in Article Scopus (7)

Crossref

Google Scholar

George J.

Lim J.S.

Jang S.J.

Cun Y.

Ozretić L.

Kong G.

Leenders F.

Lu X.

Fernández-Cuesta L.

Bosco G.

et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 524 : 47-53 View in Article Scopus (647)

PubMed

Crossref

Google Scholar

Gökbuget N.

Dombret H.

Bonifacio M.

Reichle A.

Graux C.

Faul C.

Diedrich H.

Topp M.S.

Brüggemann M.

Horst H.A.

et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131 : 1522-1531 View in Article Scopus (166)

PubMed

Crossref

Google Scholar

Graeber C. The Breakthrough: Immunotherapy and the Race to Cure Cancer. Scribe Publications , London, UK View in Article Google Scholar

Grasso C.S.

Giannakis M.

Wells D.K.

Hamada T.

Mu X.J.

Quist M.

Nowak J.A.

Nishihara R.

Qian Z.R.

Inamura K.

et al. Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 8 : 730-749 View in Article Scopus (91)

PubMed

Crossref

Google Scholar

Griss J.

Bauer W.

Wagner C.

Simon M.

Chen M.

Grabmeier-Pfistershammer K.

Maurer-Granofszky M.

Roka F.

Penz T.

Bock C.

et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10 : 4186 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Grupp S.A.

Kalos M.

Barrett D.

Aplenc R.

Porter D.L.

Rheingold S.R.

Teachey D.T.

Chew A.

Hauck B.

Wright J.F.

et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 : 1509-1518 View in Article Scopus (1799)

PubMed

Crossref

Google Scholar

Guo X.

Zhang Y.

Zheng L.

Zheng C.

Song J.

Zhang Q.

Kang B.

Liu Z.

Jin L.

Xing R.

et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24 : 978-985 View in Article Scopus (111)

PubMed

Crossref

Google Scholar

Hamid O.

Robert C.

Daud A.

Hodi F.S.

Hwu W.-J.

Kefford R.

Wolchok J.D.

Hersey P.

Joseph R.W.

Weber J.S.

et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. J. Clin. Oncol. 36 ( ) View in Article Crossref

Google Scholar

Hamid O.

Molinero L.

Bolen C.R.

Sosman J.A.

Muñoz-Couselo E.

Kluger H.M.

McDermott D.F.

Powderly J.D.

Sarkar I.

Ballinger M.

et al. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin. Cancer Res. 25 : 6061-6072 https://doi.org/10.1158/1078-0432.CCR-18-3488 View in Article Scopus (7)

PubMed

Crossref

Google Scholar

Hegde P.S.

Karanikas V.

Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin. Cancer Res. 22 : 1865-1874 View in Article Scopus (208)

PubMed

Crossref

Google Scholar

Hellmann M.D.

Ciuleanu T.E.

Pluzanski A.

Lee J.S.

Otterson G.A.

Audigier-Valette C.

Minenza E.

Linardou H.

Burgers S.

Salman P.

et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 378 : 2093-2104 View in Article Scopus (878)

PubMed

Crossref

Google Scholar

Herbst R.S.

Soria J.C.

Kowanetz M.

Fine G.D.

Hamid O.

Gordon M.S.

Sosman J.A.

McDermott D.F.

Powderly J.D.

Gettinger S.N.

et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515 : 563-567 View in Article Scopus (2444)

PubMed

Crossref

Google Scholar

Herbst R.S.

Lopes G.

Kowalski D.M.

Nishio M.

Wu Y.-L.

de Castro Junior, G.

Baas P.

Kim D.-W.

Gubens M.A.

Cristescu R.

et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and –042 trials. Ann. Oncol. 30 : v851-v934 View in Article Abstract

Full Text PDF

Google Scholar

Hochster H.S.

Bendell J.C.

Cleary J.M.

Foster P.

Zhang W.

He X.

Hernandez G.

Iizuka K.

Eckhardt S.G. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). J. Clin. Oncol. 35 : 673 View in Article Crossref

Google Scholar

Hodi F.S.

Hwu W.J.

Kefford R.

Weber J.S.

Daud A.

Hamid O.

Patnaik A.

Ribas A.

Robert C.

Gangadhar T.C.

et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J. Clin. Oncol. 34 : 1510-1517 View in Article Scopus (363)

PubMed

Crossref

Google Scholar

Hodi F.S.

Ballinger M.

Lyons B.

Soria J.C.

Nishino M.

Tabernero J.

Powles T.

Smith D.

Hoos A.

McKenna C.

et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J. Clin. Oncol. 36 : 850-858 View in Article Scopus (85)

PubMed

Crossref

Google Scholar

Hoffmann P.

Hofmeister R.

Brischwein K.

Brandl C.

Crommer S.

Bargou R.

Itin C.

Prang N.

Baeuerle P.A. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer. 115 : 98-104 View in Article Scopus (200)

PubMed

Crossref

Google Scholar

Homet Moreno B.

Zaretsky J.M.

Garcia-Diaz A.

Tsoi J.

Parisi G.

Robert L.

Meeth K.

Ndoye A.

Bosenberg M.

Weeraratna A.T.

et al. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol. Res. 4 : 845-857 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Huang A.Y.

Gulden P.H.

Woods A.S.

Thomas M.C.

Tong C.D.

Wang W.

Engelhard V.H.

Pasternack G.

Cotter R.

Hunt D.

et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 93 : 9730-9735 View in Article Scopus (282)

PubMed

Crossref

Google Scholar

Iglesia M.D.

Parker J.S.

Hoadley K.A.

Serody J.S.

Perou C.M.

Vincent B.G. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J. Natl. Cancer Inst. 108 https://doi.org/10.1093/jnci/djw1144 View in Article PubMed

Crossref

Google Scholar

Ikeda M.

Sung M.W.

Kudo M.

Kobayashi M.

Baron A.D.

Finn R.S.

Kaneko S.

Zhu A.X.

Kubota T.

Kralijevic S.

et al. A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. EMSO 2019 Congress. Cancer Res. 79 : v253-v324 View in Article Google Scholar

Jamal-Hanjani M.

Wilson G.A.

McGranahan N.

Birkbak N.J.

Watkins T.B.K.

Veeriah S.

Shafi S.

Johnson D.H.

Mitter R.

Rosenthal R.

et al.

TRACERx Consortium Tracking the Evolution of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 376 : 2109-2121 View in Article Scopus (633)

PubMed

Crossref

Google Scholar

Joshi K.

Robert de Massy M.

Ismail M.

Reading J.L.

Uddin I.

Woolston A.

Hatipoglu E.

Oakes T.

Rosenthal R.

Peacock T.

et al.

TRACERx Consortium Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25 : 1549-1559 https://doi.org/10.1038/s41591-019-0592-2 View in Article Scopus (13)

PubMed

Crossref

Google Scholar

Jotte R.M.

Cappuzzo F.

Vynnychenko I.

Stroyakovskiy D.

Rodriguez Abreu D.

Hussein M.A.

Soo R.A.

Conter H.J.

Kozuki T.

Silva C.

et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J. Clin. Ontol. 36 ( ) View in Article Google Scholar

Kantarjian H.

Stein A.

Gökbuget N.

Fielding A.K.

Schuh A.C.

Ribera J.M.

Wei A.

Dombret H.

Foà R.

Bassan R.

et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 376 : 836-847 View in Article Scopus (483)

PubMed

Crossref

Google Scholar

Kobold S.

Pantelyushin S.

Rataj F.

Vom Berg J. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Front. Oncol. 8 : 285 View in Article PubMed

Crossref

Google Scholar

Köhnke T.

Krupka C.

Tischer J.

Knösel T.

Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J. Hematol. Oncol. 8 : 111 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Kowanetz M.

Zou W.

Gettinger S.N.

Koeppen H.

Kockx M.

Schmid P.

Kadel 3rd, E.E.

Wistuba I.

Chaft J.

Rizvi N.A.

et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc. Natl. Acad. Sci. USA. 115 : E10119-E10126 View in Article Scopus (48)

PubMed

Crossref

Google Scholar

Landi L.

D’Incà F.

Gelibter A.

Chiari R.

Grossi F.

Delmonte A.

Passaro A.

Signorelli D.

Gelsomino F.

Galetta D.

et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J. Immunother. Cancer. 7 : 316 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Lechner M.G.

Karimi S.S.

Barry-Holson K.

Angell T.E.

Murphy K.A.

Church C.H.

Ohlfest J.R.

Hu P.

Epstein A.L. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36 : 477-489 View in Article Scopus (92)

PubMed

Crossref

Google Scholar

Lee M.

Ryoo B.

Hsu C.

Numata K.

Stein S.

Verret W.

Hack S.

Spahn J.

Liu B.

Abdullah H.

He R.

Lee K. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, hepatocellular carcinoma (HCC). ESMO 2019 Congress. Ann. Oncol. 30 : v851-v934 View in Article Google Scholar

Li J.

Piskol R.

Ybarra R.

Chen Y.J.

Li J.

Slaga D.

Hristopoulos M.

Clark R.

Modrusan Z.

Totpal K.

et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11 : eaax8861 https://doi.org/10.1126/scitranslmed.aax8861 View in Article Scopus (10)

PubMed

Crossref

Google Scholar

Lukas R.V.

Rodon J.

Becker K.

Wong E.T.

Shih K.

Touat M.

Fasso M.

Osborne S.

Molinero L.

O’Hear C.

et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol. 140 : 317-328 View in Article Scopus (19)

PubMed

Crossref

Google Scholar

Marabelle A.

Fakih M.G.

Lopez J.

Shah M.

Shapira-Frommer R.

Nakagawa K.

Chung H.C.

Kindler H.L.

Lopez-Martin J.A.

Miller A.

et al. Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. ESMO 2019 Congress. Ann. Oncol. 30 : v475-v532 View in Article Abstract

Full Text PDF

Google Scholar

Mariathasan S.

Turley S.J.

Nickles D.

Castiglioni A.

Yuen K.

Wang Y.

Kadel III, E.E.

Koeppen H.

Astarita J.L.

Cubas R.

et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 554 : 544-548 View in Article Scopus (523)

PubMed

Crossref

Google Scholar

Massard C.

Gordon M.S.

Sharma S.

Rafii S.

Wainberg Z.A.

Luke J.

Curiel T.J.

Colon-Otero G.

Hamid O.

Sanborn R.E.

et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34 : 3119-3125 View in Article Scopus (431)

PubMed

Crossref

Google Scholar

May M.T.

Gompels M.

Delpech V.

Porter K.

Orkin C.

Kegg S.

Hay P.

Johnson M.

Palfreeman A.

Gilson R.

et al.

UK Collaborative HIV Cohort (UK CHIC) Study Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 28 : 1193-1202 View in Article Scopus (258)

PubMed

Crossref

Google Scholar

McDermott D.F.

Huseni M.A.

Atkins M.B.

Motzer R.J.

Rini B.I.

Escudier B.

Fong L.

Joseph R.W.

Pal S.K.

Reeves J.A.

et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24 : 749-757 View in Article Scopus (204)

PubMed

Crossref

Google Scholar

McGranahan N.

Furness A.J.

Rosenthal R.

Ramskov S.

Lyngaa R.

Saini S.K.

Jamal-Hanjani M.

Wilson G.A.

Birkbak N.J.

Hiley C.T.

et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 351 : 1463-1469 View in Article Scopus (1082)

PubMed

Crossref

Google Scholar

Mellman I.

Hubbard-Lucey V.M.

Tontonoz M.J.

Kalos M.D.

Chen D.S.

Allison J.P.

Drake C.G.

Levitsky H.

Lonberg N.

van der Burg S.H.

et al. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol. Res. 4 : 279-288 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Mosely S.I.

Prime J.E.

Sainson R.C.

Koopmann J.O.

Wang D.Y.

Greenawalt D.M.

Ahdesmaki M.J.

Leyland R.

Mullins S.

Pacelli L.

et al. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunol. Res. 5 : 29-41 View in Article Scopus (83)

PubMed

Crossref

Google Scholar

Motzer R.J.

Penkov K.

Haanen J.B.A.G.

Rini B.I.

Albiges L.

Campbell M.T.

Kollmannsberger C.K.

Negrier S.

Uemura M.

Lee J.L.

et al. LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann. Oncol. 29 ( ) View in Article Abstract

Full Text

Full Text PDF

Google Scholar

Motzer R.J.

Tannir N.M.

McDermott D.F.

Arén Frontera O.

Melichar B.

Choueiri T.K.

Plimack E.R.

Barthélémy P.

Porta C.

George S.

et al.

CheckMate 214 Investigators Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 378 : 1277-1290 View in Article Scopus (893)

PubMed

Crossref

Google Scholar

Nass S.J.

Rothenberg M.L.

Pentz R.

Hricak H.

Abernethy A.

Anderson K.

Gee A.W.

Harvey R.D.

Piantadosi S.

Bertagnolli M.M.

et al. Accelerating anticancer drug development - opportunities and trade-offs. Nat. Rev. Clin. Oncol. 15 : 777-786 View in Article Scopus (5)

PubMed

Crossref

Google Scholar

Neelapu S.S.

Locke F.L.

Bartlett N.L.

Lekakis L.J.

Miklos D.B.

Jacobson C.A.

Braunschweig I.

Oluwole O.O.

Siddiqi T.

Lin Y.

et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 377 : 2531-2544 View in Article Scopus (874)

PubMed

Crossref

Google Scholar

Olnes M.J.

Kotliarov Y.

Biancotto A.

Cheung F.

Chen J.

Shi R.

Zhou H.

Wang E.

Tsang J.S.

Nussenblatt R.

Consortium C.H.I.

CHI Consortium Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci. Rep. 6 : 23002 View in Article Scopus (44)

PubMed

Crossref

Google Scholar

Oyama T.

Ran S.

Ishida T.

Nadaf S.

Kerr L.

Carbone D.P.

Gabrilovich D.I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160 : 1224-1232 View in Article PubMed

Google Scholar

Panda A.

de Cubas A.A.

Stein M.

Riedlinger G.

Kra J.

Mayer T.

Smith C.C.

Vincent B.G.

Serody J.S.

Beckermann K.E.

et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight. 3 : 121522 https://doi.org/10.1172/jci.insight.121522 View in Article Scopus (20)

PubMed

Crossref

Google Scholar

Pao W.

Ooi C.H.

Birzele F.

Ruefli-Brasse A.

Cannarile M.A.

Reis B.

Scharf S.H.

Schubert D.A.

Hatje K.

Pelletier N.

et al. Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer. Cancer Discov. 8 : 395-402 View in Article Scopus (15)

PubMed

Crossref

Google Scholar

Paz-Ares L.

Luft A.

Vicente D.

Tafreshi A.

Gümüş M.

Mazières J.

Hermes B.

Çay Şenler F.

Csőszi T.

Fülöp A.

et al.

KEYNOTE-407 Investigators Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 379 : 2040-2051 View in Article Scopus (525)

PubMed

Crossref

Google Scholar

Perea F.

Bernal M.

Sánchez-Palencia A.

Carretero J.

Torres C.

Bayarri C.

Gómez-Morales M.

Garrido F.

Ruiz-Cabello F. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. Int. J. Cancer. 140 : 888-899 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Pereira C.

Gimenez-Xavier P.

Pros E.

Pajares M.J.

Moro M.

Gomez A.

Navarro A.

Condom E.

Moran S.

Gomez-Lopez G.

et al. Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. Clin. Cancer Res. 23 : 3203-3213 View in Article PubMed

Crossref

Google Scholar

Peters S.

Cho B.C.

Reinmuth N.

Lee K.H.

Luft A.

Ahn M.-J.

Baas P.

Dols M.C.

Smolin A.

Vicente D.

et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy [abstract]. In Proceedings of the American Association for Cancer Research Annual Meeting 2019 (AACR). Cancer Res. 79 View in Article PubMed

Google Scholar

Peters S.

Ramalingam S.S.

Paz-Ares L.

Bernabe Caro R.

Zurawski B.

Kim S.

Alexandru A.

Lupinacci L.

de la Mora Jimenez E.

Sakai H.

et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis. Ann. Oncol. 30 : v851-v934 View in Article Abstract

Full Text PDF

Google Scholar

Pillai R.N.

Kamphorst R.O.

Owonikoko T.K.

Behera M.

Pakkala S.

Khuri F.R.

Ahmed R.

Ramalingam S.S. Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 34 View in Article Crossref

Google Scholar

Purbhoo M.A.

Irvine D.J.

Huppa J.B.

Davis M.M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5 : 524-530 View in Article Scopus (359)

PubMed

Crossref

Google Scholar

Reck M.

Rodríguez-Abreu D.

Robinson A.G.

Hui R.

Csőszi T.

Fülöp A.

Gottfried M.

Peled N.

Tafreshi A.

Cuffe S.

et al.

KEYNOTE-024 Investigators Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 : 1823-1833 View in Article PubMed

Crossref

Google Scholar

Redman J.M.

Steinberg S.M.

Gulley J.L. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J. Immunother. Cancer. 6 : 91 View in Article Scopus (9)

PubMed

Crossref

Google Scholar

Restifo N.P.

Marincola F.M.

Kawakami Y.

Taubenberger J.

Yannelli J.R.

Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88 : 100-108 View in Article Scopus (347)

PubMed

Crossref

Google Scholar

Rini B.I.

Powles T.

Chen M.

Puhlmann M.

Atkins M.B. Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC). J. Clin. Ontol. 35 ( ) View in Article Google Scholar

Rizvi N.A.

Hellmann M.D.

Snyder A.

Kvistborg P.

Makarov V.

Havel J.J.

Lee W.

Yuan J.

Wong P.

Ho T.S.

et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348 : 124-128 View in Article Scopus (3386)

PubMed

Crossref

Google Scholar

Rizvi N.A.

Chul Cho B.

Reinmuth N.

Lee K.H.

Ahn M.J.

Luft A.

van den Heuvel M.

Cobo M.

Smolin A.

Vicente D.

et al. LBA6 Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. ESMO Immuno-Oncology Congress 2018Ann. Oncol. 29 : x39-x43 View in Article Google Scholar

Robbins P.F.

Kassim S.H.

Tran T.L.

Crystal J.S.

Morgan R.A.

Feldman S.A.

Yang J.C.

Dudley M.E.

Wunderlich J.R.

Sherry R.M.

et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21 : 1019-1027 View in Article Scopus (322)

PubMed

Crossref

Google Scholar

Rosenthal R.

Cadieux E.L.

Salgado R.

Bakir M.A.

Moore D.A.

Hiley C.T.

Lund T.

Tanić M.

Reading J.L.

Joshi K.

et al.

TRACERx consortium Neoantigen-directed immune escape in lung cancer evolution. Nature. 567 : 479-485 View in Article Scopus (100)

PubMed

Crossref

Google Scholar

Salmon H.

Franciszkiewicz K.

Damotte D.

Dieu-Nosjean M.C.

Validire P.

Trautmann A.

Mami-Chouaib F.

Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122 : 899-910 View in Article Scopus (254)

PubMed

Crossref

Google Scholar

Samstein R.M.

Lee C.H.

Shoushtari A.N.

Hellmann M.D.

Shen R.

Janjigian Y.Y.

Barron D.A.

Zehir A.

Jordan E.J.

Omuro A.

et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51 : 202-206 View in Article Scopus (322)

PubMed

Crossref

Google Scholar

Scheper W.

Kelderman S.

Fanchi L.F.

Linnemann C.

Bendle G.

de Rooij M.A.J.

Hirt C.

Mezzadra R.

Slagter M.

Dijkstra K.

et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25 : 89-94 View in Article Scopus (72)

PubMed

Crossref

Google Scholar

Schuster S.J.

Bishop M.R.

Tam C.

Borchmann P.

Jaeger U.

Waller E.K.

Holte H.

McGuirk J.P.

Jaglowski S.

Tobinai K.

et al. Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. Blood. 132 ( ) View in Article Google Scholar

Shields A.F.

Jacobs P.M.

Sznol M.

Graham M.M.

Germain R.N.

Lum L.G.

Jaffee E.M.

de Vries E.G.E.

Nimmagadda S.

Van den Abbeele A.D.

et al. Immune Modulation Therapy and Imaging: Workshop Report. J. Nucl. Med. 59 : 410-417 View in Article Scopus (11)

PubMed

Crossref

Google Scholar

Shrimali R.K.

Ahmad S.

Verma V.

Zeng P.

Ananth S.

Gaur P.

Gittelman R.M.

Yusko E.

Sanders C.

Robins H.

et al. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis. Cancer Immunol. Res. 5 : 755-766 View in Article Scopus (62)

PubMed

Crossref

Google Scholar

Simoni Y.

Becht E.

Fehlings M.

Loh C.Y.

Koo S.L.

Teng K.W.W.

Yeong J.P.S.

Nahar R.

Zhang T.

Kared H.

et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 557 : 575-579 View in Article Scopus (189)

PubMed

Crossref

Google Scholar

Smith C.C.

Beckermann K.E.

Bortone D.S.

De Cubas A.A.

Bixby L.M.

Lee S.J.

Panda A.

Ganesan S.

Bhanot G.

Wallen E.M.

et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J. Clin. Invest. 128 : 4804-4820 View in Article Scopus (29)

PubMed

Crossref

Google Scholar

Spigel D.

de Marinis F.

Giaccone G.

Reinmuth N.

Vergnenegre A.

Barrios C.H.

Morise M.

Felip E.

Andric Z.G.

Geater S.

et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. EMSO 2019 Congress. Ann. Oncol. 30 : v851-v934 View in Article Google Scholar

Spranger S.

Koblish H.K.

Horton B.

Scherle P.A.

Newton R.

Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer. 2 https://doi.org/10.1186/2051-1426-2-3 View in Article Scopus (280)

PubMed

Crossref

Google Scholar

Takahashi Y.

Harashima N.

Kajigaya S.

Yokoyama H.

Cherkasova E.

McCoy J.P.

Hanada K.

Mena O.

Kurlander R.

Tawab A.

et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J. Clin. Invest. 118 : 1099-1109 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Tran E.

Robbins P.F.

Lu Y.C.

Prickett T.D.

Gartner J.J.

Jia L.

Pasetto A.

Zheng Z.

Ray S.

Groh E.M.

et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 375 : 2255-2262 View in Article PubMed

Crossref

Google Scholar

Tsimberidou A.M.

Levit L.A.

Schilsky R.L.

Averbuch S.D.

Chen D.

Kirkwood J.M.

McShane L.M.

Sharon E.

Mileham K.F.

Postow M.A. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J. Immunother. Cancer. 6 : 108 View in Article Scopus (2)

PubMed

Crossref

Google Scholar

Tumeh P.C.

Harview C.L.

Yearley J.H.

Shintaku I.P.

Taylor E.J.

Robert L.

Chmielowski B.

Spasic M.

Henry G.

Ciobanu V.

et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515 : 568-571 View in Article Scopus (2623)

PubMed

Crossref

Google Scholar

Tumeh P.C.

Hellmann M.D.

Hamid O.

Tsai K.K.

Loo K.L.

Gubens M.A.

Rosenblum M.

Harview C.L.

Taube J.M.

Handley N.

et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol. Res. 5 : 417-424 View in Article Scopus (94)

PubMed

Crossref

Google Scholar

Varadarajan N.

Julg B.

Yamanaka Y.J.

Chen H.

Ogunniyi A.O.

McAndrew E.

Porter L.C.

Piechocka-Trocha A.

Hill B.J.

Douek D.C.

et al. A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis. J. Clin. Invest. 121 : 4322-4331 View in Article Scopus (108)

PubMed

Crossref

Google Scholar

von Pawel J.

Syrigos K.

Mazieres J.

Cortinovis D.

Dziadziuszko R.

Gandara D.R.

Conkling P.

Goldschmidt J.

Thomas C.A.

Bordoni R.

et al. 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann. Oncol. 28 : mdx380.017 View in Article Abstract

Full Text

Full Text PDF

Google Scholar

Wang D.Y.

Eroglu Z.

Ozgun A.

Leger P.D.

Zhao S.

Ye F.

Luke J.J.

Joseph R.W.

Haq R.

Ott P.A.

et al. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol. Res. 5 : 357-362 View in Article Scopus (7)

PubMed

Crossref

Google Scholar

Weber J.S.

Hodi F.S.

Wolchok J.D.

Topalian S.L.

Schadendorf D.

Larkin J.

Sznol M.

Long G.V.

Li H.

Waxman I.M.

et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J. Clin. Oncol. 35 : 785-792 View in Article Scopus (371)

PubMed

Crossref

Google Scholar

Wolchok J.D.

Hoos A.

O’Day S.

Weber J.S.

Hamid O.

Lebbe C.

Maio M.

Binder M.

Bohnsack O.

Nichol G.

et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15 : 7412-7420 View in Article Scopus (2022)

PubMed

Crossref

Google Scholar

Zhou X.

Liu S.

Kim E.S.

Herbst R.S.

Lee J.J. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin. Trials. 5 : 181-193 View in Article Scopus (0)

PubMed

Crossref

Google Scholar